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Summary
Herpes zoster, caused by varicella zoster virus (VZV) 
reactivation, affects mainly the adult population, 
although it can occur in children. this happens when 
primary infection (varicella) has occurred at a very young 
age or in immunocompromised patients. Complications 
are rare in healthy individuals. they include VZV 
cutaneous dissemination, which affects 2%–10% of 
immunocompromised patients.
We present a previously healthy child, with history of 
varicella during her first month of life, which presented 
at age 8 with a severe case of herpes zoster, complicated 
with cutaneous dissemination. Immunity study was 
unremarkable. Causes, management and follow-up are 
discussed.
BaCkground
Herpes zoster, or shingles, is a viral cutaneous 
infection caused by varicella zoster virus (VZV) 
reactivation, manifested by painful vesicular lesions 
grouped together along an area corresponding 
to one or, less frequently, more dermatomes.1 2 
Usually it is a benign, self-limited and well-tolerated 
pathology.3 4 
While chickenpox is considered a childhood 
disease, herpes zoster mainly affects adults. From 
age 0 to 14 years the incidence is low (0.45 cases 
per 1000 individuals/year), especially in immuno-
competent children. It is more frequently described 
when VZV primary infection (varicella) occurred in 
utero or during the first year of life.2
Cutaneous dissemination is a complication that 
affects 2%–10% of immunocompromised patients, 
being rare in the immunocompetent, especially 
at paediatric age.5 This complication manifests 
3 to 4 days after the onset of dermatome-associ-
ated lesions. Cutaneous dissemination occurs due 
to transitory viraemia during viral reactivation.6 7 
Other complications of herpes zoster must be kept 
in mind if cutaneous dissemination occurs, as 
viraemia can lead to the infection of other organs 
such has the brain, kidneys, lungs and liver,8 which 
can be life threatening, especially in severely immu-
nocompromised patients.6
CaSe preSenTaTion
An 8-year-old girl was admitted in our unit for eval-
uation and treatment of an extensive papulovesic-
ular rash.
Her symptoms had started 9 days prior to 
hospitalisation when she complained of electric 
shock-like pain in the area corresponding to the 
right cervical plexus (between the jaw and clavicle). 
Three days later, she developed an itchy erythem-
atous papular rash over the right postauricular 
region which extended to adjacent scalp, cervical 
region and shoulder and subsequently became 
vesicular. She was evaluated by her paediatrician 
who diagnosed herpes zoster and started acetamin-
ophen. After 3 days, the rash progressed, extending 
eventually to her thorax, abdomen and limbs, 
affecting palms and soles. She also developed fever 
(maximum 38.0°C every 3 hours).
Of note, her medical history was remarkable 
for varicella infection during her first month of 
life. She was born full term, following an uncom-
plicated pregnancy and had no history sugges-
tive of immunocompromising conditions. Her 
growth and development were normal. She also 
had history of cutaneous reaction to amoxicillin at 
the age of 3, atopic dermatitis and allergic rhinitis 
(pollen). Her vaccination schedule did not include 
varicella vaccine, which is optional in our country; 
as so, antibodies to varicella were not checked 
after the infection. Family history was irrelevant, 
except for parental consanguinity (second degree 
cousins).
At admission, she had normal vital signs and 
was febrile. She presented with exuberant lesions, 
mainly vesicles and scabs (and some pustules), most 
of them in coalescence, distributed over the areas 
described above—corresponding to cervical plexus 
and C6 dermatomes (figure 1). Subjacent tissue 
presented erythema and oedema. Erythematous 
papules and vesicles were present through thorax 
(figure 2), abdomen and limbs. Remaining physical 
examination was unremarkable.
inveSTigaTionS
Complete blood count was normal and C reac-
tive protein was 8.91 mg/L. Renal function, iono-
gram and liver transaminases were normal. Blood 
VZV DNA screening was positive. Blood culture 
was negative. Given the extension of the affected 
area and the presence of disseminated lesions, HIV 
serologies, flow cytometry and quantitative immu-
noglobulins test were performed—results were 
unremarkable.
TreaTmenT
The child was admitted to our Unit and started 
acyclovir 1500 mg/m2/day intravenously. Given the 
concern about secondary infection antibiotics were 
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added (flucloxacillin 150 mg/kg/day intravenously and clinda-
mycin 30 mg/kg/day intravenously).
ouTCome and follow-up
Fever subsided 3 days later. After an initial flare up, the localised 
and disseminated lesions began to improve. At day 8 of medica-
tion, she developed a generalised macular-papular rash affecting 
palms and soles, leading to flucloxacillin and clindamycin suspen-
sion. Cytomegalovirus, Epstein-Barr virus, parvovirus B19 and 
Mycoplasma pneumoniae blood serologies were negative. At 
day 10 of acyclovir, the child re-initiated electric shock-like 
pain in the affected cervical area, requiring tramadol prescrip-
tion to control pain during that day. She completed 14 days of 
acyclovir. She was discharged after 15 days, with symptomatic 
treatment for residual pain and cutaneous care of remaining 
lesions. The pain subsided a few days after the discharge. During 
the following year, she was followed up in paediatric consul-
tation—immunological screening was repeated and came out 
normal. There were no relapses or complications.
diSCuSSion
Herpes zoster involvement of multiple dermatomes and cuta-
neous dissemination is rare in immunocompetent children.2 A 
study about herpes zoster complications concluded that cuta-
neous dissemination was the only complication with statistically 
significant difference between immunocompetent and immuno-
compromised children.9 Therefore, children who present with 
this complication should be tested for immunodeficiency and 
malignancy. Ideally, tests should be done 1 month after the disease 
presentation. In our case, given the severity of manifestations, 
we chose to do it in the acute phase of the disease and to repeat 
it later, during follow-up in paediatric consultation. In this child, 
whose immunity test were unremarkable, the extension of the 
affected area and cutaneous dissemination were probably related 
to the fact that the she had varicella during her first month of 
life—in this period, due to immune system immaturity and pres-
ence of maternal antibodies, an effective immunity against this 
virus is difficult to obtain.10 Universal varicella vaccination is not 
implemented in some countries, including ours. One of the main 
reasons for that was the concern that the widespread use of vari-
cella vaccine would lead to an increase of herpes zoster cases in 
the adult population who had natural infection in the past.11 The 
circulation of the wild-type virus was thought to be important 
for mantaining long-term immunity and prevent VZV reactiva-
tion. However, recent studies do not support this hypothesis.12 
Although the attenuated vaccine virus can reactivate and cause 
herpes zoster, it does it less frequently than the wild-type virus. 
Therefore, universal immunisation would ultimately lead to a 
global reduction in the incidence of herpes zoster.6
Acyclovir (orally: 40–60 mg/kg/day; intravenously: 30 mg/
kg/day or 1500 mg/m2/day if <12 years) for 7–10 days is the 
treatment of choice for herpes zoster and should be initiated in 
the first 72 hours,13 to decrease the duration and severity of the 
disease.7 Treatment can be extended if new vesicles continue to 
arise (until 2 days after the last ones appear) or while complica-
tions persist.13 Once our patient had complicated herpes zoster 
and re-initiated pain in day 10 of acyclovir, we decided to extend 
treatment to 14 days.
Usually, herpes zoster resolves in 1–3 weeks.13 Sequels such as 
postherpetic neuralgia (pain that lasts >4 months since the arise 
of skin lesions) are rare in children—nevertheless, it is important 
to follow-up these patients during enough time to exclude its 
development.9 In our patient, no sequelae were documented.
figure 1 Zoster lesions in coalescence (vesicles, scabs and some 
pustules), at admission. Subjacent tissue with erythema and oedema, 
more pronounced on the ear.
figure 2 Disseminated cutaneous lesions (papules and vesicles) on 
thorax, at admission.
learning points
 ► Herpes zoster is rare in children but can happen when 
varicella occurred in the first year of life or in utero.
 ► Rare complications of herpes zoster should prompt a 
thorough screening for immunodeficiency and malignancy.
 ► Children should be followed-up for postherpetic neuralgia, a 
rare but important sequel.
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